nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—FYN—stomach cancer	0.27	0.595	CbGaD
Vandetanib—VEGFA—stomach cancer	0.0868	0.192	CbGaD
Vandetanib—EGFR—stomach cancer	0.0732	0.162	CbGaD
Vandetanib—EGFR—Docetaxel—stomach cancer	0.0638	0.275	CbGbCtD
Vandetanib—ALB—stomach cancer	0.0233	0.0515	CbGaD
Vandetanib—ABCC1—Epirubicin—stomach cancer	0.0221	0.0951	CbGbCtD
Vandetanib—ABCC1—Irinotecan—stomach cancer	0.0215	0.0925	CbGbCtD
Vandetanib—ABCC1—Docetaxel—stomach cancer	0.0157	0.0678	CbGbCtD
Vandetanib—ABCG2—Irinotecan—stomach cancer	0.0144	0.0619	CbGbCtD
Vandetanib—ABCG2—Fluorouracil—stomach cancer	0.0138	0.0594	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—stomach cancer	0.0117	0.0506	CbGbCtD
Vandetanib—ABCC1—Methotrexate—stomach cancer	0.0114	0.049	CbGbCtD
Vandetanib—ABCG2—Docetaxel—stomach cancer	0.0105	0.0454	CbGbCtD
Vandetanib—ALB—Irinotecan—stomach cancer	0.00991	0.0427	CbGbCtD
Vandetanib—ALB—Fluorouracil—stomach cancer	0.00951	0.041	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—stomach cancer	0.00785	0.0338	CbGbCtD
Vandetanib—ABCG2—Methotrexate—stomach cancer	0.00761	0.0328	CbGbCtD
Vandetanib—ALB—Methotrexate—stomach cancer	0.00524	0.0226	CbGbCtD
Vandetanib—CYP3A4—Irinotecan—stomach cancer	0.00311	0.0134	CbGbCtD
Vandetanib—CYP3A4—Docetaxel—stomach cancer	0.00228	0.0098	CbGbCtD
Vandetanib—ORM1—bile—stomach cancer	0.00191	0.0254	CbGeAlD
Vandetanib—CYP3A4—Doxorubicin—stomach cancer	0.0017	0.00731	CbGbCtD
Vandetanib—FLT4—blood vessel—stomach cancer	0.00106	0.0141	CbGeAlD
Vandetanib—RIPK2—blood vessel—stomach cancer	0.00105	0.014	CbGeAlD
Vandetanib—Afatinib—ERBB2—stomach cancer	0.000995	0.239	CrCbGaD
Vandetanib—BLK—hematopoietic system—stomach cancer	0.000993	0.0132	CbGeAlD
Vandetanib—PTK6—hematopoietic system—stomach cancer	0.000941	0.0125	CbGeAlD
Vandetanib—TEK—blood vessel—stomach cancer	0.000849	0.0113	CbGeAlD
Vandetanib—PLK4—hematopoietic system—stomach cancer	0.000775	0.0103	CbGeAlD
Vandetanib—SRC—blood vessel—stomach cancer	0.000754	0.01	CbGeAlD
Vandetanib—Bosutinib—FYN—stomach cancer	0.000754	0.181	CrCbGaD
Vandetanib—TYRO3—hematopoietic system—stomach cancer	0.000728	0.00969	CbGeAlD
Vandetanib—LYN—hematopoietic system—stomach cancer	0.000724	0.00964	CbGeAlD
Vandetanib—BLK—lymphoid tissue—stomach cancer	0.000699	0.0093	CbGeAlD
Vandetanib—KDR—blood vessel—stomach cancer	0.000694	0.00924	CbGeAlD
Vandetanib—PLK4—Topotecan—Irinotecan—stomach cancer	0.000684	0.257	CbGdCrCtD
Vandetanib—PTK6—digestive system—stomach cancer	0.000654	0.00871	CbGeAlD
Vandetanib—BMPR1B—epithelium—stomach cancer	0.000652	0.00868	CbGeAlD
Vandetanib—FLT3—hematopoietic system—stomach cancer	0.000619	0.00824	CbGeAlD
Vandetanib—PDGFRB—blood vessel—stomach cancer	0.000601	0.00799	CbGeAlD
Vandetanib—ABL1—Topotecan—Irinotecan—stomach cancer	0.000575	0.216	CbGdCrCtD
Vandetanib—PDGFRB—gall bladder—stomach cancer	0.000565	0.00752	CbGeAlD
Vandetanib—FLT4—hematopoietic system—stomach cancer	0.000562	0.00748	CbGeAlD
Vandetanib—RIPK2—hematopoietic system—stomach cancer	0.000559	0.00744	CbGeAlD
Vandetanib—IRAK4—hematopoietic system—stomach cancer	0.000546	0.00727	CbGeAlD
Vandetanib—PLK4—lymphoid tissue—stomach cancer	0.000546	0.00726	CbGeAlD
Vandetanib—PTK6—endocrine gland—stomach cancer	0.000541	0.0072	CbGeAlD
Vandetanib—ERBB3—hematopoietic system—stomach cancer	0.000535	0.00712	CbGeAlD
Vandetanib—ORM1—gall bladder—stomach cancer	0.00053	0.00706	CbGeAlD
Vandetanib—Gefitinib—CHEK2—stomach cancer	0.00052	0.125	CrCbGaD
Vandetanib—FLT4—epithelium—stomach cancer	0.000514	0.00684	CbGeAlD
Vandetanib—TYRO3—lymphoid tissue—stomach cancer	0.000513	0.00682	CbGeAlD
Vandetanib—Bosutinib—CHEK2—stomach cancer	0.000512	0.123	CrCbGaD
Vandetanib—RIPK2—epithelium—stomach cancer	0.000511	0.0068	CbGeAlD
Vandetanib—LYN—lymphoid tissue—stomach cancer	0.00051	0.00679	CbGeAlD
Vandetanib—EPHA5—digestive system—stomach cancer	0.000506	0.00674	CbGeAlD
Vandetanib—MKNK1—hematopoietic system—stomach cancer	0.000502	0.00669	CbGeAlD
Vandetanib—PLK4—bone marrow—stomach cancer	0.000497	0.00661	CbGeAlD
Vandetanib—FGR—hematopoietic system—stomach cancer	0.000496	0.00661	CbGeAlD
Vandetanib—RET—hematopoietic system—stomach cancer	0.000496	0.00661	CbGeAlD
Vandetanib—AXL—hematopoietic system—stomach cancer	0.000494	0.00658	CbGeAlD
Vandetanib—STK35—pancreas—stomach cancer	0.000494	0.00657	CbGeAlD
Vandetanib—VEGFA—smooth muscle tissue—stomach cancer	0.000491	0.00654	CbGeAlD
Vandetanib—ERBB3—epithelium—stomach cancer	0.000489	0.00651	CbGeAlD
Vandetanib—Afatinib—EGFR—stomach cancer	0.00047	0.113	CrCbGaD
Vandetanib—ALB—gall bladder—stomach cancer	0.000465	0.00619	CbGeAlD
Vandetanib—FYN—hematopoietic system—stomach cancer	0.000463	0.00616	CbGeAlD
Vandetanib—VEGFA—pancreas—stomach cancer	0.000454	0.00604	CbGeAlD
Vandetanib—RET—epithelium—stomach cancer	0.000454	0.00604	CbGeAlD
Vandetanib—TEK—hematopoietic system—stomach cancer	0.000452	0.00602	CbGeAlD
Vandetanib—MAP4K5—hematopoietic system—stomach cancer	0.000452	0.00602	CbGeAlD
Vandetanib—EPHA6—endocrine gland—stomach cancer	0.000451	0.006	CbGeAlD
Vandetanib—PLK4—endocrine gland—stomach cancer	0.000445	0.00593	CbGeAlD
Vandetanib—ERBB3—pancreas—stomach cancer	0.000436	0.0058	CbGeAlD
Vandetanib—FLT3—lymphoid tissue—stomach cancer	0.000436	0.0058	CbGeAlD
Vandetanib—AXL—smooth muscle tissue—stomach cancer	0.000435	0.00579	CbGeAlD
Vandetanib—TYRO3—endocrine gland—stomach cancer	0.000418	0.00557	CbGeAlD
Vandetanib—EPHA5—endocrine gland—stomach cancer	0.000418	0.00557	CbGeAlD
Vandetanib—YES1—hematopoietic system—stomach cancer	0.000418	0.00556	CbGeAlD
Vandetanib—LYN—endocrine gland—stomach cancer	0.000416	0.00554	CbGeAlD
Vandetanib—STK10—hematopoietic system—stomach cancer	0.000414	0.00551	CbGeAlD
Vandetanib—TEK—epithelium—stomach cancer	0.000413	0.0055	CbGeAlD
Vandetanib—BMPR1B—endocrine gland—stomach cancer	0.00041	0.00545	CbGeAlD
Vandetanib—FYN—smooth muscle tissue—stomach cancer	0.000408	0.00542	CbGeAlD
Vandetanib—SRC—hematopoietic system—stomach cancer	0.000402	0.00535	CbGeAlD
Vandetanib—MAP4K5—smooth muscle tissue—stomach cancer	0.000398	0.0053	CbGeAlD
Vandetanib—TEK—smooth muscle tissue—stomach cancer	0.000398	0.0053	CbGeAlD
Vandetanib—FLT3—bone marrow—stomach cancer	0.000397	0.00528	CbGeAlD
Vandetanib—FLT4—lymphoid tissue—stomach cancer	0.000396	0.00527	CbGeAlD
Vandetanib—BLK—lymph node—stomach cancer	0.000394	0.00525	CbGeAlD
Vandetanib—LTK—lymph node—stomach cancer	0.00039	0.00519	CbGeAlD
Vandetanib—RIPK2—digestive system—stomach cancer	0.000389	0.00517	CbGeAlD
Vandetanib—SLK—pancreas—stomach cancer	0.000387	0.00516	CbGeAlD
Vandetanib—FMO1—digestive system—stomach cancer	0.000386	0.00513	CbGeAlD
Vandetanib—IRAK4—lymphoid tissue—stomach cancer	0.000384	0.00512	CbGeAlD
Vandetanib—ERBB3—lymphoid tissue—stomach cancer	0.000377	0.00501	CbGeAlD
Vandetanib—LYN—liver—stomach cancer	0.000375	0.00499	CbGeAlD
Vandetanib—ERBB3—digestive system—stomach cancer	0.000372	0.00495	CbGeAlD
Vandetanib—KDR—hematopoietic system—stomach cancer	0.00037	0.00492	CbGeAlD
Vandetanib—MAP4K5—pancreas—stomach cancer	0.000368	0.0049	CbGeAlD
Vandetanib—TEK—pancreas—stomach cancer	0.000368	0.0049	CbGeAlD
Vandetanib—YES1—smooth muscle tissue—stomach cancer	0.000368	0.00489	CbGeAlD
Vandetanib—SRC—epithelium—stomach cancer	0.000367	0.00489	CbGeAlD
Vandetanib—FLT4—bone marrow—stomach cancer	0.00036	0.0048	CbGeAlD
Vandetanib—RIPK2—bone marrow—stomach cancer	0.000358	0.00477	CbGeAlD
Vandetanib—VEGFA—bone marrow—stomach cancer	0.000357	0.00476	CbGeAlD
Vandetanib—FLT3—endocrine gland—stomach cancer	0.000356	0.00473	CbGeAlD
Vandetanib—SRC—smooth muscle tissue—stomach cancer	0.000354	0.00471	CbGeAlD
Vandetanib—MKNK1—lymphoid tissue—stomach cancer	0.000354	0.00471	CbGeAlD
Vandetanib—IRAK4—bone marrow—stomach cancer	0.00035	0.00466	CbGeAlD
Vandetanib—MKNK1—digestive system—stomach cancer	0.000349	0.00465	CbGeAlD
Vandetanib—FGR—lymphoid tissue—stomach cancer	0.000349	0.00465	CbGeAlD
Vandetanib—RET—lymphoid tissue—stomach cancer	0.000349	0.00465	CbGeAlD
Vandetanib—STK35—endocrine gland—stomach cancer	0.000348	0.00464	CbGeAlD
Vandetanib—AXL—lymphoid tissue—stomach cancer	0.000348	0.00463	CbGeAlD
Vandetanib—RET—digestive system—stomach cancer	0.000345	0.00459	CbGeAlD
Vandetanib—FGR—digestive system—stomach cancer	0.000345	0.00459	CbGeAlD
Vandetanib—YES1—pancreas—stomach cancer	0.00034	0.00453	CbGeAlD
Vandetanib—KDR—epithelium—stomach cancer	0.000338	0.0045	CbGeAlD
Vandetanib—Erlotinib—EGFR—stomach cancer	0.000332	0.0797	CrCbGaD
Vandetanib—SRC—pancreas—stomach cancer	0.000327	0.00435	CbGeAlD
Vandetanib—FYN—lymphoid tissue—stomach cancer	0.000326	0.00434	CbGeAlD
Vandetanib—KDR—smooth muscle tissue—stomach cancer	0.000325	0.00433	CbGeAlD
Vandetanib—FLT4—endocrine gland—stomach cancer	0.000323	0.0043	CbGeAlD
Vandetanib—MKNK1—bone marrow—stomach cancer	0.000322	0.00429	CbGeAlD
Vandetanib—FYN—digestive system—stomach cancer	0.000322	0.00428	CbGeAlD
Vandetanib—RIPK2—endocrine gland—stomach cancer	0.000321	0.00428	CbGeAlD
Vandetanib—FLT3—liver—stomach cancer	0.000321	0.00427	CbGeAlD
Vandetanib—PDGFRB—hematopoietic system—stomach cancer	0.00032	0.00426	CbGeAlD
Vandetanib—FMO1—endocrine gland—stomach cancer	0.000319	0.00424	CbGeAlD
Vandetanib—TEK—lymphoid tissue—stomach cancer	0.000318	0.00424	CbGeAlD
Vandetanib—MAP4K5—lymphoid tissue—stomach cancer	0.000318	0.00424	CbGeAlD
Vandetanib—FGR—bone marrow—stomach cancer	0.000318	0.00423	CbGeAlD
Vandetanib—LCK—bone marrow—stomach cancer	0.000318	0.00423	CbGeAlD
Vandetanib—STK35—liver—stomach cancer	0.000314	0.00418	CbGeAlD
Vandetanib—PLK4—lymph node—stomach cancer	0.000308	0.0041	CbGeAlD
Vandetanib—ERBB3—endocrine gland—stomach cancer	0.000308	0.00409	CbGeAlD
Vandetanib—ABL2—liver—stomach cancer	0.000306	0.00407	CbGeAlD
Vandetanib—SLK—bone marrow—stomach cancer	0.000305	0.00406	CbGeAlD
Vandetanib—ORM1—hematopoietic system—stomach cancer	0.0003	0.00399	CbGeAlD
Vandetanib—EGFR—liver—stomach cancer	0.000299	0.00398	CbGeAlD
Vandetanib—FYN—bone marrow—stomach cancer	0.000297	0.00395	CbGeAlD
Vandetanib—YES1—lymphoid tissue—stomach cancer	0.000294	0.00391	CbGeAlD
Vandetanib—PDGFRB—epithelium—stomach cancer	0.000292	0.00389	CbGeAlD
Vandetanib—STK10—lymphoid tissue—stomach cancer	0.000291	0.00388	CbGeAlD
Vandetanib—FLT4—liver—stomach cancer	0.000291	0.00388	CbGeAlD
Vandetanib—YES1—digestive system—stomach cancer	0.00029	0.00386	CbGeAlD
Vandetanib—MAP4K5—bone marrow—stomach cancer	0.00029	0.00386	CbGeAlD
Vandetanib—RIPK2—liver—stomach cancer	0.00029	0.00386	CbGeAlD
Vandetanib—VEGFA—liver—stomach cancer	0.000289	0.00384	CbGeAlD
Vandetanib—MKNK1—endocrine gland—stomach cancer	0.000289	0.00384	CbGeAlD
Vandetanib—STK10—digestive system—stomach cancer	0.000288	0.00383	CbGeAlD
Vandetanib—FMO1—liver—stomach cancer	0.000287	0.00382	CbGeAlD
Vandetanib—FGR—endocrine gland—stomach cancer	0.000285	0.0038	CbGeAlD
Vandetanib—RET—endocrine gland—stomach cancer	0.000285	0.0038	CbGeAlD
Vandetanib—ABL1—hematopoietic system—stomach cancer	0.000285	0.00379	CbGeAlD
Vandetanib—AXL—endocrine gland—stomach cancer	0.000284	0.00378	CbGeAlD
Vandetanib—BMPR1B—lymph node—stomach cancer	0.000283	0.00377	CbGeAlD
Vandetanib—IRAK4—liver—stomach cancer	0.000283	0.00376	CbGeAlD
Vandetanib—SRC—lymphoid tissue—stomach cancer	0.000283	0.00376	CbGeAlD
Vandetanib—PDGFRB—smooth muscle tissue—stomach cancer	0.000282	0.00375	CbGeAlD
Vandetanib—SRC—digestive system—stomach cancer	0.000279	0.00372	CbGeAlD
Vandetanib—ERBB3—liver—stomach cancer	0.000277	0.00369	CbGeAlD
Vandetanib—FMO3—endocrine gland—stomach cancer	0.000275	0.00367	CbGeAlD
Vandetanib—YES1—bone marrow—stomach cancer	0.000268	0.00356	CbGeAlD
Vandetanib—FYN—endocrine gland—stomach cancer	0.000266	0.00354	CbGeAlD
Vandetanib—STK10—bone marrow—stomach cancer	0.000265	0.00353	CbGeAlD
Vandetanib—PDGFRB—pancreas—stomach cancer	0.00026	0.00347	CbGeAlD
Vandetanib—MKNK1—liver—stomach cancer	0.00026	0.00346	CbGeAlD
Vandetanib—KDR—lymphoid tissue—stomach cancer	0.00026	0.00346	CbGeAlD
Vandetanib—MAP4K5—endocrine gland—stomach cancer	0.00026	0.00346	CbGeAlD
Vandetanib—TEK—endocrine gland—stomach cancer	0.00026	0.00346	CbGeAlD
Vandetanib—FGR—liver—stomach cancer	0.000257	0.00342	CbGeAlD
Vandetanib—LCK—liver—stomach cancer	0.000257	0.00342	CbGeAlD
Vandetanib—KDR—digestive system—stomach cancer	0.000257	0.00342	CbGeAlD
Vandetanib—AXL—liver—stomach cancer	0.000256	0.00341	CbGeAlD
Vandetanib—ABL1—smooth muscle tissue—stomach cancer	0.000251	0.00334	CbGeAlD
Vandetanib—FMO3—liver—stomach cancer	0.000248	0.00331	CbGeAlD
Vandetanib—SLK—liver—stomach cancer	0.000247	0.00328	CbGeAlD
Vandetanib—FLT3—lymph node—stomach cancer	0.000246	0.00327	CbGeAlD
Vandetanib—STK35—lymph node—stomach cancer	0.000241	0.00321	CbGeAlD
Vandetanib—YES1—endocrine gland—stomach cancer	0.00024	0.00319	CbGeAlD
Vandetanib—FYN—liver—stomach cancer	0.00024	0.00319	CbGeAlD
Vandetanib—STK10—endocrine gland—stomach cancer	0.000238	0.00316	CbGeAlD
Vandetanib—KDR—bone marrow—stomach cancer	0.000237	0.00315	CbGeAlD
Vandetanib—ABL2—lymph node—stomach cancer	0.000235	0.00312	CbGeAlD
Vandetanib—MAP4K5—liver—stomach cancer	0.000234	0.00312	CbGeAlD
Vandetanib—TEK—liver—stomach cancer	0.000234	0.00312	CbGeAlD
Vandetanib—ABL1—pancreas—stomach cancer	0.000232	0.00309	CbGeAlD
Vandetanib—SRC—endocrine gland—stomach cancer	0.000231	0.00307	CbGeAlD
Vandetanib—EGFR—lymph node—stomach cancer	0.000229	0.00305	CbGeAlD
Vandetanib—PDGFRB—lymphoid tissue—stomach cancer	0.000225	0.003	CbGeAlD
Vandetanib—FLT4—lymph node—stomach cancer	0.000223	0.00297	CbGeAlD
Vandetanib—PDGFRB—digestive system—stomach cancer	0.000222	0.00296	CbGeAlD
Vandetanib—RIPK2—lymph node—stomach cancer	0.000222	0.00296	CbGeAlD
Vandetanib—VEGFA—lymph node—stomach cancer	0.000222	0.00295	CbGeAlD
Vandetanib—FMO1—lymph node—stomach cancer	0.00022	0.00293	CbGeAlD
Vandetanib—IRAK4—lymph node—stomach cancer	0.000217	0.00289	CbGeAlD
Vandetanib—YES1—liver—stomach cancer	0.000216	0.00288	CbGeAlD
Vandetanib—STK10—liver—stomach cancer	0.000214	0.00285	CbGeAlD
Vandetanib—ERBB3—lymph node—stomach cancer	0.000213	0.00283	CbGeAlD
Vandetanib—KDR—endocrine gland—stomach cancer	0.000212	0.00283	CbGeAlD
Vandetanib—MAP2K5—endocrine gland—stomach cancer	0.000212	0.00283	CbGeAlD
Vandetanib—SRC—liver—stomach cancer	0.000208	0.00277	CbGeAlD
Vandetanib—Gefitinib—EGFR—stomach cancer	0.000208	0.0499	CrCbGaD
Vandetanib—PDGFRB—bone marrow—stomach cancer	0.000205	0.00273	CbGeAlD
Vandetanib—Bosutinib—EGFR—stomach cancer	0.000205	0.0491	CrCbGaD
Vandetanib—ABL1—lymphoid tissue—stomach cancer	0.000201	0.00267	CbGeAlD
Vandetanib—MKNK1—lymph node—stomach cancer	0.0002	0.00266	CbGeAlD
Vandetanib—ABL1—digestive system—stomach cancer	0.000198	0.00264	CbGeAlD
Vandetanib—FGR—lymph node—stomach cancer	0.000197	0.00262	CbGeAlD
Vandetanib—RET—lymph node—stomach cancer	0.000197	0.00262	CbGeAlD
Vandetanib—LCK—lymph node—stomach cancer	0.000197	0.00262	CbGeAlD
Vandetanib—AXL—lymph node—stomach cancer	0.000196	0.00261	CbGeAlD
Vandetanib—ORM1—bone marrow—stomach cancer	0.000192	0.00256	CbGeAlD
Vandetanib—KDR—liver—stomach cancer	0.000191	0.00255	CbGeAlD
Vandetanib—MAP2K5—liver—stomach cancer	0.000191	0.00255	CbGeAlD
Vandetanib—FMO3—lymph node—stomach cancer	0.00019	0.00253	CbGeAlD
Vandetanib—SLK—lymph node—stomach cancer	0.000189	0.00252	CbGeAlD
Vandetanib—PDGFRB—endocrine gland—stomach cancer	0.000184	0.00245	CbGeAlD
Vandetanib—FYN—lymph node—stomach cancer	0.000184	0.00245	CbGeAlD
Vandetanib—ABL1—bone marrow—stomach cancer	0.000183	0.00243	CbGeAlD
Vandetanib—TEK—lymph node—stomach cancer	0.00018	0.00239	CbGeAlD
Vandetanib—MAP4K5—lymph node—stomach cancer	0.00018	0.00239	CbGeAlD
Vandetanib—ORM1—endocrine gland—stomach cancer	0.000172	0.00229	CbGeAlD
Vandetanib—EPHB6—lymph node—stomach cancer	0.000172	0.00228	CbGeAlD
Vandetanib—YES1—lymph node—stomach cancer	0.000166	0.00221	CbGeAlD
Vandetanib—PDGFRB—liver—stomach cancer	0.000166	0.00221	CbGeAlD
Vandetanib—STK10—lymph node—stomach cancer	0.000164	0.00219	CbGeAlD
Vandetanib—ABL1—endocrine gland—stomach cancer	0.000164	0.00218	CbGeAlD
Vandetanib—PLK4—Idarubicin—Epirubicin—stomach cancer	0.000161	0.0605	CbGdCrCtD
Vandetanib—PLK4—Doxorubicin—Epirubicin—stomach cancer	0.000161	0.0605	CbGdCrCtD
Vandetanib—SRC—lymph node—stomach cancer	0.00016	0.00212	CbGeAlD
Vandetanib—ORM1—liver—stomach cancer	0.000155	0.00207	CbGeAlD
Vandetanib—PLK4—Idarubicin—Doxorubicin—stomach cancer	0.000149	0.056	CbGdCrCtD
Vandetanib—PLK4—Epirubicin—Doxorubicin—stomach cancer	0.000149	0.056	CbGdCrCtD
Vandetanib—ABL1—liver—stomach cancer	0.000148	0.00197	CbGeAlD
Vandetanib—KDR—lymph node—stomach cancer	0.000147	0.00195	CbGeAlD
Vandetanib—MAP2K5—lymph node—stomach cancer	0.000147	0.00195	CbGeAlD
Vandetanib—ALB—liver—stomach cancer	0.000136	0.00181	CbGeAlD
Vandetanib—ABL1—Doxorubicin—Epirubicin—stomach cancer	0.000135	0.0508	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—stomach cancer	0.000135	0.0508	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Epirubicin—stomach cancer	0.000135	0.0508	CbGdCrCtD
Vandetanib—PDGFRB—lymph node—stomach cancer	0.000127	0.00169	CbGeAlD
Vandetanib—CYP3A4—hematopoietic system—stomach cancer	0.000125	0.00167	CbGeAlD
Vandetanib—ABL1—Epirubicin—Doxorubicin—stomach cancer	0.000125	0.047	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—stomach cancer	0.000125	0.047	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—stomach cancer	0.000125	0.047	CbGdCrCtD
Vandetanib—ORM1—lymph node—stomach cancer	0.000119	0.00159	CbGeAlD
Vandetanib—ABCG2—bone marrow—stomach cancer	0.000115	0.00153	CbGeAlD
Vandetanib—ABL1—lymph node—stomach cancer	0.000113	0.00151	CbGeAlD
Vandetanib—ABCC1—liver—stomach cancer	0.000113	0.0015	CbGeAlD
Vandetanib—Erlotinib—ALB—stomach cancer	0.000106	0.0254	CrCbGaD
Vandetanib—ALB—lymph node—stomach cancer	0.000105	0.00139	CbGeAlD
Vandetanib—ABCG2—liver—stomach cancer	9.31e-05	0.00124	CbGeAlD
Vandetanib—CYP3A4—digestive system—stomach cancer	8.71e-05	0.00116	CbGeAlD
Vandetanib—ABCC1—lymph node—stomach cancer	8.63e-05	0.00115	CbGeAlD
Vandetanib—CYP3A4—endocrine gland—stomach cancer	7.2e-05	0.000958	CbGeAlD
Vandetanib—ABCG2—lymph node—stomach cancer	7.14e-05	0.00095	CbGeAlD
Vandetanib—Hypertension—Capecitabine—stomach cancer	6.73e-05	0.000729	CcSEcCtD
Vandetanib—Dry mouth—Docetaxel—stomach cancer	6.71e-05	0.000727	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—stomach cancer	6.7e-05	0.000726	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—stomach cancer	6.7e-05	0.000726	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—stomach cancer	6.67e-05	0.000722	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—stomach cancer	6.66e-05	0.000722	CcSEcCtD
Vandetanib—Chest pain—Capecitabine—stomach cancer	6.64e-05	0.000719	CcSEcCtD
Vandetanib—Arthralgia—Capecitabine—stomach cancer	6.64e-05	0.000719	CcSEcCtD
Vandetanib—Haematuria—Epirubicin—stomach cancer	6.63e-05	0.000718	CcSEcCtD
Vandetanib—Gefitinib—ALB—stomach cancer	6.63e-05	0.0159	CrCbGaD
Vandetanib—Anxiety—Capecitabine—stomach cancer	6.62e-05	0.000717	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	6.59e-05	0.000714	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—stomach cancer	6.59e-05	0.000713	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—stomach cancer	6.58e-05	0.000713	CcSEcCtD
Vandetanib—Hepatobiliary disease—Epirubicin—stomach cancer	6.57e-05	0.000712	CcSEcCtD
Vandetanib—Oedema—Docetaxel—stomach cancer	6.57e-05	0.000712	CcSEcCtD
Vandetanib—Epistaxis—Epirubicin—stomach cancer	6.56e-05	0.00071	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—stomach cancer	6.54e-05	0.000708	CcSEcCtD
Vandetanib—Infection—Docetaxel—stomach cancer	6.53e-05	0.000708	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—stomach cancer	6.53e-05	0.000707	CcSEcCtD
Vandetanib—Sinusitis—Epirubicin—stomach cancer	6.52e-05	0.000707	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—stomach cancer	6.51e-05	0.000705	CcSEcCtD
Vandetanib—Diarrhoea—Irinotecan—stomach cancer	6.51e-05	0.000705	CcSEcCtD
Vandetanib—Dry mouth—Capecitabine—stomach cancer	6.49e-05	0.000703	CcSEcCtD
Vandetanib—CYP3A4—liver—stomach cancer	6.49e-05	0.000863	CbGeAlD
Vandetanib—Pneumonia—Doxorubicin—stomach cancer	6.47e-05	0.000701	CcSEcCtD
Vandetanib—Nervous system disorder—Docetaxel—stomach cancer	6.45e-05	0.000698	CcSEcCtD
Vandetanib—Pruritus—Fluorouracil—stomach cancer	6.44e-05	0.000698	CcSEcCtD
Vandetanib—Thrombocytopenia—Docetaxel—stomach cancer	6.44e-05	0.000697	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—stomach cancer	6.43e-05	0.000697	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—stomach cancer	6.43e-05	0.000697	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—stomach cancer	6.43e-05	0.000696	CcSEcCtD
Vandetanib—Skin disorder—Docetaxel—stomach cancer	6.38e-05	0.000692	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—stomach cancer	6.38e-05	0.000691	CcSEcCtD
Vandetanib—Oedema—Capecitabine—stomach cancer	6.36e-05	0.00069	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—stomach cancer	6.35e-05	0.000688	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—stomach cancer	6.32e-05	0.000685	CcSEcCtD
Vandetanib—Infection—Capecitabine—stomach cancer	6.32e-05	0.000685	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—stomach cancer	6.3e-05	0.000683	CcSEcCtD
Vandetanib—Dizziness—Irinotecan—stomach cancer	6.29e-05	0.000681	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—stomach cancer	6.27e-05	0.00068	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—stomach cancer	6.27e-05	0.000679	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—stomach cancer	6.25e-05	0.000677	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—stomach cancer	6.25e-05	0.000677	CcSEcCtD
Vandetanib—Nervous system disorder—Capecitabine—stomach cancer	6.24e-05	0.000676	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—stomach cancer	6.24e-05	0.000676	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—stomach cancer	6.23e-05	0.000675	CcSEcCtD
Vandetanib—Diarrhoea—Fluorouracil—stomach cancer	6.23e-05	0.000675	CcSEcCtD
Vandetanib—Thrombocytopenia—Capecitabine—stomach cancer	6.23e-05	0.000675	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—stomach cancer	6.19e-05	0.000671	CcSEcCtD
Vandetanib—Skin disorder—Capecitabine—stomach cancer	6.18e-05	0.00067	CcSEcCtD
Vandetanib—Urinary tract disorder—Epirubicin—stomach cancer	6.16e-05	0.000668	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—stomach cancer	6.13e-05	0.000664	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—stomach cancer	6.12e-05	0.000663	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—stomach cancer	6.08e-05	0.000659	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—stomach cancer	6.07e-05	0.000657	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—stomach cancer	6.05e-05	0.000655	CcSEcCtD
Vandetanib—Vomiting—Irinotecan—stomach cancer	6.05e-05	0.000655	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—stomach cancer	6.03e-05	0.000654	CcSEcCtD
Vandetanib—Dizziness—Fluorouracil—stomach cancer	6.02e-05	0.000652	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—stomach cancer	6.01e-05	0.000652	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—stomach cancer	6.01e-05	0.000651	CcSEcCtD
Vandetanib—Rash—Irinotecan—stomach cancer	6e-05	0.00065	CcSEcCtD
Vandetanib—Dermatitis—Irinotecan—stomach cancer	5.99e-05	0.000649	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Docetaxel—stomach cancer	5.99e-05	0.000649	CcSEcCtD
Vandetanib—Headache—Irinotecan—stomach cancer	5.96e-05	0.000645	CcSEcCtD
Vandetanib—Insomnia—Docetaxel—stomach cancer	5.95e-05	0.000644	CcSEcCtD
Vandetanib—Paraesthesia—Docetaxel—stomach cancer	5.9e-05	0.000639	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—stomach cancer	5.9e-05	0.000639	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—stomach cancer	5.89e-05	0.000638	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—stomach cancer	5.88e-05	0.000637	CcSEcCtD
Vandetanib—Dyspnoea—Docetaxel—stomach cancer	5.86e-05	0.000635	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—stomach cancer	5.84e-05	0.000633	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—stomach cancer	5.83e-05	0.000632	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—stomach cancer	5.8e-05	0.000629	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—stomach cancer	5.8e-05	0.000629	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Capecitabine—stomach cancer	5.8e-05	0.000628	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—stomach cancer	5.79e-05	0.000627	CcSEcCtD
Vandetanib—Vomiting—Fluorouracil—stomach cancer	5.79e-05	0.000627	CcSEcCtD
Vandetanib—Dyspepsia—Docetaxel—stomach cancer	5.79e-05	0.000627	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—stomach cancer	5.77e-05	0.000626	CcSEcCtD
Vandetanib—Insomnia—Capecitabine—stomach cancer	5.76e-05	0.000624	CcSEcCtD
Vandetanib—Rash—Fluorouracil—stomach cancer	5.74e-05	0.000622	CcSEcCtD
Vandetanib—Dermatitis—Fluorouracil—stomach cancer	5.74e-05	0.000622	CcSEcCtD
Vandetanib—Paraesthesia—Capecitabine—stomach cancer	5.71e-05	0.000619	CcSEcCtD
Vandetanib—Decreased appetite—Docetaxel—stomach cancer	5.71e-05	0.000619	CcSEcCtD
Vandetanib—Headache—Fluorouracil—stomach cancer	5.71e-05	0.000618	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—stomach cancer	5.7e-05	0.000618	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—stomach cancer	5.68e-05	0.000616	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Docetaxel—stomach cancer	5.67e-05	0.000615	CcSEcCtD
Vandetanib—Dyspnoea—Capecitabine—stomach cancer	5.67e-05	0.000615	CcSEcCtD
Vandetanib—Fatigue—Docetaxel—stomach cancer	5.67e-05	0.000614	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—stomach cancer	5.66e-05	0.000613	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—stomach cancer	5.66e-05	0.000613	CcSEcCtD
Vandetanib—Nausea—Irinotecan—stomach cancer	5.65e-05	0.000612	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—stomach cancer	5.62e-05	0.000609	CcSEcCtD
Vandetanib—Pain—Docetaxel—stomach cancer	5.62e-05	0.000609	CcSEcCtD
Vandetanib—Constipation—Docetaxel—stomach cancer	5.62e-05	0.000609	CcSEcCtD
Vandetanib—Dyspepsia—Capecitabine—stomach cancer	5.6e-05	0.000607	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—stomach cancer	5.57e-05	0.000604	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—stomach cancer	5.56e-05	0.000603	CcSEcCtD
Vandetanib—Decreased appetite—Capecitabine—stomach cancer	5.53e-05	0.000599	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—stomach cancer	5.51e-05	0.000597	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Capecitabine—stomach cancer	5.49e-05	0.000595	CcSEcCtD
Vandetanib—Fatigue—Capecitabine—stomach cancer	5.49e-05	0.000594	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—stomach cancer	5.47e-05	0.000593	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—stomach cancer	5.47e-05	0.000592	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—stomach cancer	5.46e-05	0.000592	CcSEcCtD
Vandetanib—Constipation—Capecitabine—stomach cancer	5.44e-05	0.00059	CcSEcCtD
Vandetanib—Pain—Capecitabine—stomach cancer	5.44e-05	0.00059	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—stomach cancer	5.43e-05	0.000589	CcSEcCtD
Vandetanib—Nausea—Fluorouracil—stomach cancer	5.41e-05	0.000586	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—stomach cancer	5.4e-05	0.000585	CcSEcCtD
Vandetanib—Gastrointestinal pain—Docetaxel—stomach cancer	5.37e-05	0.000582	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—stomach cancer	5.36e-05	0.000581	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—stomach cancer	5.32e-05	0.000576	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—stomach cancer	5.24e-05	0.000568	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—stomach cancer	5.22e-05	0.000566	CcSEcCtD
Vandetanib—Gastrointestinal pain—Capecitabine—stomach cancer	5.2e-05	0.000564	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—stomach cancer	5.2e-05	0.000564	CcSEcCtD
Vandetanib—Body temperature increased—Docetaxel—stomach cancer	5.2e-05	0.000563	CcSEcCtD
Vandetanib—Abdominal pain—Docetaxel—stomach cancer	5.2e-05	0.000563	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—stomach cancer	5.16e-05	0.000559	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—stomach cancer	5.12e-05	0.000555	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—stomach cancer	5.1e-05	0.000553	CcSEcCtD
Vandetanib—Cough—Methotrexate—stomach cancer	5.07e-05	0.000549	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—stomach cancer	5.06e-05	0.000548	CcSEcCtD
Vandetanib—Abdominal pain—Capecitabine—stomach cancer	5.03e-05	0.000545	CcSEcCtD
Vandetanib—Body temperature increased—Capecitabine—stomach cancer	5.03e-05	0.000545	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—stomach cancer	5.03e-05	0.000545	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—stomach cancer	5.03e-05	0.000545	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—stomach cancer	4.94e-05	0.000535	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—stomach cancer	4.94e-05	0.000535	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—stomach cancer	4.92e-05	0.000533	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	4.91e-05	0.000532	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—stomach cancer	4.83e-05	0.000524	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—stomach cancer	4.77e-05	0.000517	CcSEcCtD
Vandetanib—Cough—Epirubicin—stomach cancer	4.74e-05	0.000514	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—stomach cancer	4.74e-05	0.000513	CcSEcCtD
Vandetanib—Asthenia—Docetaxel—stomach cancer	4.72e-05	0.000511	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—stomach cancer	4.71e-05	0.00051	CcSEcCtD
Vandetanib—Infection—Methotrexate—stomach cancer	4.71e-05	0.00051	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—stomach cancer	4.69e-05	0.000508	CcSEcCtD
Vandetanib—Pruritus—Docetaxel—stomach cancer	4.65e-05	0.000504	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—stomach cancer	4.65e-05	0.000503	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—stomach cancer	4.64e-05	0.000503	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—stomach cancer	4.62e-05	0.000501	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—stomach cancer	4.62e-05	0.000501	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—stomach cancer	4.61e-05	0.000499	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—stomach cancer	4.6e-05	0.000499	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	4.59e-05	0.000498	CcSEcCtD
Vandetanib—Asthenia—Capecitabine—stomach cancer	4.57e-05	0.000495	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—stomach cancer	4.52e-05	0.00049	CcSEcCtD
Vandetanib—Pruritus—Capecitabine—stomach cancer	4.5e-05	0.000488	CcSEcCtD
Vandetanib—Diarrhoea—Docetaxel—stomach cancer	4.5e-05	0.000487	CcSEcCtD
Vandetanib—Oedema—Epirubicin—stomach cancer	4.43e-05	0.00048	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—stomach cancer	4.42e-05	0.000479	CcSEcCtD
Vandetanib—Infection—Epirubicin—stomach cancer	4.4e-05	0.000477	CcSEcCtD
Vandetanib—Cough—Doxorubicin—stomach cancer	4.39e-05	0.000475	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—stomach cancer	4.35e-05	0.000472	CcSEcCtD
Vandetanib—Diarrhoea—Capecitabine—stomach cancer	4.35e-05	0.000472	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—stomach cancer	4.35e-05	0.000471	CcSEcCtD
Vandetanib—Dizziness—Docetaxel—stomach cancer	4.35e-05	0.000471	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—stomach cancer	4.34e-05	0.00047	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—stomach cancer	4.34e-05	0.00047	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—stomach cancer	4.32e-05	0.000468	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—stomach cancer	4.31e-05	0.000467	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—stomach cancer	4.28e-05	0.000464	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—stomach cancer	4.28e-05	0.000464	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—stomach cancer	4.28e-05	0.000464	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—stomach cancer	4.26e-05	0.000462	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—stomach cancer	4.25e-05	0.000461	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	4.25e-05	0.00046	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—stomach cancer	4.22e-05	0.000458	CcSEcCtD
Vandetanib—Dizziness—Capecitabine—stomach cancer	4.21e-05	0.000456	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—stomach cancer	4.19e-05	0.000453	CcSEcCtD
Vandetanib—Vomiting—Docetaxel—stomach cancer	4.18e-05	0.000453	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—stomach cancer	4.17e-05	0.000452	CcSEcCtD
Vandetanib—Rash—Docetaxel—stomach cancer	4.14e-05	0.000449	CcSEcCtD
Vandetanib—Dermatitis—Docetaxel—stomach cancer	4.14e-05	0.000449	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—stomach cancer	4.12e-05	0.000446	CcSEcCtD
Vandetanib—Headache—Docetaxel—stomach cancer	4.12e-05	0.000446	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—stomach cancer	4.1e-05	0.000444	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—stomach cancer	4.09e-05	0.000443	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—stomach cancer	4.08e-05	0.000443	CcSEcCtD
Vandetanib—Infection—Doxorubicin—stomach cancer	4.08e-05	0.000442	CcSEcCtD
Vandetanib—Pain—Methotrexate—stomach cancer	4.05e-05	0.000439	CcSEcCtD
Vandetanib—Vomiting—Capecitabine—stomach cancer	4.05e-05	0.000438	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—stomach cancer	4.04e-05	0.000438	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—stomach cancer	4.02e-05	0.000436	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—stomach cancer	4.02e-05	0.000435	CcSEcCtD
Vandetanib—Rash—Capecitabine—stomach cancer	4.01e-05	0.000435	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—stomach cancer	4.01e-05	0.000434	CcSEcCtD
Vandetanib—Dermatitis—Capecitabine—stomach cancer	4.01e-05	0.000434	CcSEcCtD
Vandetanib—Headache—Capecitabine—stomach cancer	3.99e-05	0.000432	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—stomach cancer	3.98e-05	0.000432	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—stomach cancer	3.98e-05	0.000431	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—stomach cancer	3.95e-05	0.000428	CcSEcCtD
Vandetanib—Nausea—Docetaxel—stomach cancer	3.9e-05	0.000423	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—stomach cancer	3.9e-05	0.000423	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—stomach cancer	3.87e-05	0.00042	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—stomach cancer	3.85e-05	0.000418	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—stomach cancer	3.83e-05	0.000415	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—stomach cancer	3.82e-05	0.000414	CcSEcCtD
Vandetanib—Pain—Epirubicin—stomach cancer	3.79e-05	0.000411	CcSEcCtD
Vandetanib—Constipation—Epirubicin—stomach cancer	3.79e-05	0.000411	CcSEcCtD
Vandetanib—Nausea—Capecitabine—stomach cancer	3.78e-05	0.00041	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—stomach cancer	3.75e-05	0.000406	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—stomach cancer	3.75e-05	0.000406	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—stomach cancer	3.74e-05	0.000405	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—stomach cancer	3.71e-05	0.000402	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—stomach cancer	3.68e-05	0.000399	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—stomach cancer	3.66e-05	0.000396	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—stomach cancer	3.63e-05	0.000393	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—stomach cancer	3.61e-05	0.000391	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—stomach cancer	3.57e-05	0.000386	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—stomach cancer	3.54e-05	0.000384	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—stomach cancer	3.54e-05	0.000383	CcSEcCtD
Vandetanib—Pain—Doxorubicin—stomach cancer	3.51e-05	0.00038	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—stomach cancer	3.51e-05	0.00038	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—stomach cancer	3.5e-05	0.00038	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—stomach cancer	3.5e-05	0.00038	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—stomach cancer	3.4e-05	0.000368	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—stomach cancer	3.35e-05	0.000363	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—stomach cancer	3.35e-05	0.000363	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—stomach cancer	3.24e-05	0.000351	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—stomach cancer	3.24e-05	0.000351	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—stomach cancer	3.24e-05	0.000351	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—stomach cancer	3.18e-05	0.000345	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—stomach cancer	3.14e-05	0.00034	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—stomach cancer	3.13e-05	0.000339	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—stomach cancer	3.03e-05	0.000329	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—stomach cancer	3.01e-05	0.000326	CcSEcCtD
Vandetanib—Rash—Methotrexate—stomach cancer	2.99e-05	0.000324	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—stomach cancer	2.98e-05	0.000323	CcSEcCtD
Vandetanib—Headache—Methotrexate—stomach cancer	2.97e-05	0.000322	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—stomach cancer	2.94e-05	0.000319	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—stomach cancer	2.93e-05	0.000318	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—stomach cancer	2.9e-05	0.000314	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—stomach cancer	2.82e-05	0.000305	CcSEcCtD
Vandetanib—Nausea—Methotrexate—stomach cancer	2.81e-05	0.000305	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—stomach cancer	2.81e-05	0.000304	CcSEcCtD
Vandetanib—Rash—Epirubicin—stomach cancer	2.8e-05	0.000303	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—stomach cancer	2.79e-05	0.000303	CcSEcCtD
Vandetanib—Headache—Epirubicin—stomach cancer	2.78e-05	0.000301	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—stomach cancer	2.71e-05	0.000294	CcSEcCtD
Vandetanib—Nausea—Epirubicin—stomach cancer	2.63e-05	0.000285	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—stomach cancer	2.61e-05	0.000283	CcSEcCtD
Vandetanib—Rash—Doxorubicin—stomach cancer	2.59e-05	0.00028	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—stomach cancer	2.58e-05	0.00028	CcSEcCtD
Vandetanib—Headache—Doxorubicin—stomach cancer	2.57e-05	0.000278	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—stomach cancer	2.44e-05	0.000264	CcSEcCtD
Vandetanib—SRC—Immune System—MAPK8—stomach cancer	8.65e-07	6.14e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APC—stomach cancer	8.63e-07	6.13e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL8—stomach cancer	8.63e-07	6.13e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—PIK3CA—stomach cancer	8.6e-07	6.1e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MAPK1—stomach cancer	8.59e-07	6.1e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—stomach cancer	8.59e-07	6.1e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PIK3CA—stomach cancer	8.58e-07	6.1e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—stomach cancer	8.58e-07	6.09e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—STAT3—stomach cancer	8.56e-07	6.08e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—PIK3CA—stomach cancer	8.56e-07	6.08e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CDKN1B—stomach cancer	8.56e-07	6.08e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—MAPK3—stomach cancer	8.53e-07	6.06e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—stomach cancer	8.53e-07	6.06e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—stomach cancer	8.52e-07	6.05e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—KRAS—stomach cancer	8.5e-07	6.04e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PIK3CA—stomach cancer	8.49e-07	6.03e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RHOA—stomach cancer	8.49e-07	6.03e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SERPINE1—stomach cancer	8.48e-07	6.02e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—PIK3CA—stomach cancer	8.46e-07	6.01e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MYC—stomach cancer	8.44e-07	5.99e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MAPK1—stomach cancer	8.43e-07	5.98e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDKN1B—stomach cancer	8.42e-07	5.98e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NOS3—stomach cancer	8.4e-07	5.97e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KRAS—stomach cancer	8.4e-07	5.96e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—stomach cancer	8.34e-07	5.92e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—JUN—stomach cancer	8.32e-07	5.91e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—stomach cancer	8.31e-07	5.9e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTHFR—stomach cancer	8.3e-07	5.89e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MAPK1—stomach cancer	8.25e-07	5.86e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—stomach cancer	8.25e-07	5.86e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—STAT3—stomach cancer	8.25e-07	5.86e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—stomach cancer	8.21e-07	5.83e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—CDKN1A—stomach cancer	8.18e-07	5.81e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RHOA—stomach cancer	8.18e-07	5.81e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MAPK3—stomach cancer	8.18e-07	5.81e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—stomach cancer	8.16e-07	5.8e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—stomach cancer	8.15e-07	5.79e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—JUN—stomach cancer	8.15e-07	5.78e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—stomach cancer	8.12e-07	5.77e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—MAPK1—stomach cancer	8.12e-07	5.77e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—stomach cancer	8.12e-07	5.76e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KRAS—stomach cancer	8.11e-07	5.76e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PIK3CA—stomach cancer	8.11e-07	5.76e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOS3—stomach cancer	8.1e-07	5.75e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—stomach cancer	8.09e-07	5.75e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CDKN1A—stomach cancer	8.07e-07	5.73e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—stomach cancer	8.04e-07	5.71e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PIK3CA—stomach cancer	8.03e-07	5.7e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—JUN—stomach cancer	8.02e-07	5.69e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6R—stomach cancer	8.02e-07	5.69e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PIK3CA—stomach cancer	8e-07	5.68e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—stomach cancer	7.96e-07	5.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTT1—stomach cancer	7.96e-07	5.65e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—stomach cancer	7.95e-07	5.65e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—stomach cancer	7.95e-07	5.65e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—stomach cancer	7.94e-07	5.64e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—stomach cancer	7.92e-07	5.63e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—stomach cancer	7.92e-07	5.62e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—STAT3—stomach cancer	7.91e-07	5.62e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CDKN1A—stomach cancer	7.9e-07	5.61e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK3—stomach cancer	7.88e-07	5.6e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK8—stomach cancer	7.87e-07	5.59e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2A6—stomach cancer	7.87e-07	5.59e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ERBB2—stomach cancer	7.86e-07	5.58e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—stomach cancer	7.86e-07	5.58e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—stomach cancer	7.83e-07	5.56e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—stomach cancer	7.81e-07	5.55e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—stomach cancer	7.8e-07	5.54e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—stomach cancer	7.8e-07	5.54e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—stomach cancer	7.8e-07	5.54e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MAPK1—stomach cancer	7.78e-07	5.52e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—stomach cancer	7.77e-07	5.52e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDKN1A—stomach cancer	7.77e-07	5.52e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—stomach cancer	7.77e-07	5.52e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—stomach cancer	7.72e-07	5.48e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK8—stomach cancer	7.71e-07	5.47e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—stomach cancer	7.67e-07	5.45e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—stomach cancer	7.66e-07	5.44e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CAV1—stomach cancer	7.65e-07	5.44e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKR1C3—stomach cancer	7.65e-07	5.43e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOA1—stomach cancer	7.64e-07	5.42e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—stomach cancer	7.61e-07	5.41e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—stomach cancer	7.6e-07	5.4e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK8—stomach cancer	7.59e-07	5.39e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—stomach cancer	7.58e-07	5.38e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—stomach cancer	7.57e-07	5.38e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK3—stomach cancer	7.55e-07	5.36e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—stomach cancer	7.52e-07	5.34e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SERPINE1—stomach cancer	7.51e-07	5.33e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—stomach cancer	7.5e-07	5.33e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK1—stomach cancer	7.5e-07	5.32e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—stomach cancer	7.5e-07	5.32e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—stomach cancer	7.49e-07	5.32e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—stomach cancer	7.46e-07	5.3e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ENO1—stomach cancer	7.46e-07	5.3e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—stomach cancer	7.45e-07	5.29e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—stomach cancer	7.45e-07	5.29e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—stomach cancer	7.43e-07	5.28e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—stomach cancer	7.4e-07	5.26e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—stomach cancer	7.35e-07	5.22e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	7.31e-07	5.19e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—stomach cancer	7.31e-07	5.19e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—stomach cancer	7.3e-07	5.18e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1B—stomach cancer	7.28e-07	5.17e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—stomach cancer	7.27e-07	5.16e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RHOA—stomach cancer	7.24e-07	5.14e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—stomach cancer	7.23e-07	5.13e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—stomach cancer	7.21e-07	5.12e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—stomach cancer	7.2e-07	5.11e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK1—stomach cancer	7.19e-07	5.1e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—stomach cancer	7.19e-07	5.1e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—stomach cancer	7.18e-07	5.1e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—stomach cancer	7.18e-07	5.1e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOS3—stomach cancer	7.17e-07	5.09e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—stomach cancer	7.16e-07	5.09e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—stomach cancer	7.14e-07	5.07e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—stomach cancer	7.12e-07	5.05e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—stomach cancer	7.09e-07	5.03e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—stomach cancer	7.08e-07	5.03e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—stomach cancer	7.05e-07	5e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—stomach cancer	7.05e-07	5e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1B—stomach cancer	7.01e-07	4.98e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—stomach cancer	7.01e-07	4.97e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK3—stomach cancer	6.98e-07	4.95e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—stomach cancer	6.94e-07	4.93e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—stomach cancer	6.94e-07	4.93e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—JUN—stomach cancer	6.93e-07	4.92e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—stomach cancer	6.92e-07	4.91e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—stomach cancer	6.9e-07	4.9e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK3—stomach cancer	6.88e-07	4.88e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—stomach cancer	6.83e-07	4.85e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—stomach cancer	6.79e-07	4.82e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—stomach cancer	6.78e-07	4.82e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—stomach cancer	6.76e-07	4.8e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—stomach cancer	6.75e-07	4.79e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—stomach cancer	6.74e-07	4.79e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK3—stomach cancer	6.73e-07	4.78e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—stomach cancer	6.73e-07	4.78e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1A—stomach cancer	6.72e-07	4.77e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—stomach cancer	6.7e-07	4.76e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—stomach cancer	6.69e-07	4.75e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—stomach cancer	6.69e-07	4.75e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JUN—stomach cancer	6.68e-07	4.74e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK1—stomach cancer	6.64e-07	4.71e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—stomach cancer	6.64e-07	4.71e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK3—stomach cancer	6.63e-07	4.71e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—stomach cancer	6.63e-07	4.71e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CD44—stomach cancer	6.61e-07	4.7e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—stomach cancer	6.6e-07	4.69e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK8—stomach cancer	6.56e-07	4.65e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—stomach cancer	6.55e-07	4.65e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK1—stomach cancer	6.54e-07	4.65e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—stomach cancer	6.54e-07	4.64e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—stomach cancer	6.52e-07	4.63e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—stomach cancer	6.51e-07	4.62e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—stomach cancer	6.5e-07	4.61e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—stomach cancer	6.47e-07	4.6e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1A—stomach cancer	6.47e-07	4.6e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—stomach cancer	6.45e-07	4.58e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK1—stomach cancer	6.4e-07	4.55e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—stomach cancer	6.4e-07	4.55e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—stomach cancer	6.36e-07	4.51e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—stomach cancer	6.34e-07	4.5e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK8—stomach cancer	6.32e-07	4.49e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK1—stomach cancer	6.31e-07	4.48e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—stomach cancer	6.3e-07	4.48e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—stomach cancer	6.27e-07	4.45e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—stomach cancer	6.25e-07	4.43e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—stomach cancer	6.24e-07	4.43e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—stomach cancer	6.24e-07	4.43e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1B—stomach cancer	6.21e-07	4.41e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—stomach cancer	6.18e-07	4.39e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—stomach cancer	6.05e-07	4.3e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—stomach cancer	6.05e-07	4.3e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—stomach cancer	6.02e-07	4.27e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—stomach cancer	6e-07	4.26e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—stomach cancer	5.99e-07	4.26e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—stomach cancer	5.98e-07	4.24e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—stomach cancer	5.96e-07	4.23e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—stomach cancer	5.92e-07	4.21e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JUN—stomach cancer	5.91e-07	4.2e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—stomach cancer	5.83e-07	4.14e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NOS3—stomach cancer	5.79e-07	4.11e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—stomach cancer	5.78e-07	4.1e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—stomach cancer	5.77e-07	4.1e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—stomach cancer	5.76e-07	4.09e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—stomach cancer	5.76e-07	4.09e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—stomach cancer	5.75e-07	4.08e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1A—stomach cancer	5.73e-07	4.07e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK3—stomach cancer	5.73e-07	4.07e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—stomach cancer	5.68e-07	4.03e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	5.62e-07	3.99e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK8—stomach cancer	5.59e-07	3.97e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—stomach cancer	5.57e-07	3.95e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—stomach cancer	5.56e-07	3.95e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—stomach cancer	5.52e-07	3.92e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK3—stomach cancer	5.52e-07	3.92e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTP1—stomach cancer	5.52e-07	3.92e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—stomach cancer	5.49e-07	3.9e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—stomach cancer	5.47e-07	3.89e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK1—stomach cancer	5.45e-07	3.87e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMOX1—stomach cancer	5.44e-07	3.86e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—stomach cancer	5.38e-07	3.82e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—stomach cancer	5.37e-07	3.81e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—stomach cancer	5.33e-07	3.78e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—stomach cancer	5.29e-07	3.76e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—stomach cancer	5.29e-07	3.76e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—stomach cancer	5.28e-07	3.75e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—stomach cancer	5.25e-07	3.73e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK1—stomach cancer	5.25e-07	3.73e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—stomach cancer	5.25e-07	3.73e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—stomach cancer	5.16e-07	3.67e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—stomach cancer	5.15e-07	3.65e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—stomach cancer	5.14e-07	3.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TYMS—stomach cancer	5.13e-07	3.64e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—stomach cancer	5.11e-07	3.63e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—stomach cancer	5.1e-07	3.62e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—stomach cancer	5.07e-07	3.6e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—stomach cancer	5.06e-07	3.59e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—stomach cancer	5.03e-07	3.57e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—stomach cancer	4.96e-07	3.52e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—stomach cancer	4.92e-07	3.49e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK3—stomach cancer	4.88e-07	3.47e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—stomach cancer	4.85e-07	3.44e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ERCC2—stomach cancer	4.77e-07	3.38e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—stomach cancer	4.75e-07	3.37e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—stomach cancer	4.73e-07	3.36e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK1—stomach cancer	4.65e-07	3.3e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—stomach cancer	4.65e-07	3.3e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—stomach cancer	4.57e-07	3.25e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—stomach cancer	4.56e-07	3.23e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—stomach cancer	4.48e-07	3.18e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—stomach cancer	4.41e-07	3.13e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—stomach cancer	4.39e-07	3.12e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—stomach cancer	4.37e-07	3.11e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—stomach cancer	4.21e-07	2.99e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—stomach cancer	4.19e-07	2.97e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CAV1—stomach cancer	4.13e-07	2.93e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOA1—stomach cancer	4.12e-07	2.93e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—stomach cancer	4.03e-07	2.86e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—stomach cancer	4.03e-07	2.86e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—stomach cancer	3.9e-07	2.77e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—stomach cancer	3.73e-07	2.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—stomach cancer	3.63e-07	2.58e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—stomach cancer	3.57e-07	2.54e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—stomach cancer	3.27e-07	2.32e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—stomach cancer	3.26e-07	2.31e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NOS3—stomach cancer	3.12e-07	2.22e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—stomach cancer	2.86e-07	2.03e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—stomach cancer	1.76e-07	1.25e-06	CbGpPWpGaD
